Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand

March 9, 2021 15:12:32
  • Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offering
  • Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments.
  • Cybin appears set for rapid growth as research accelerates, public acceptance grows.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and neurological conditions, has announced that it has upsized the terms of its “bought deal” offering due to strong demand. The deal size, previously announced at CDN$20,025,000, has increased to aggregate gross proceeds of CDN$30,015,000 as the underwriters have agreed to purchase 13,340,000 units of the company at CDN$2.25 per unit. Cybin intends to use the net proceeds to further develop its clinical trials, novel molecule programs and technologies enhancing the patient experience as well as for working capital and general corporate purposes.

The announced upsize comes against the backdrop of a growing demand for psychedelic companies. The burgeoning sector is attracting increasing attention from investors with more companies going public and rapidly increased research sparking greater public acceptance and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.